Genome-wide sequencing for the identification of potential genomic denominators between tumorgenesis factors in neuroblastoma and differentiated thyroid carcinoma in childre
Completed
- Conditions
- differentiated thyroid carcinomaThyroid cancer10043739
- Registration Number
- NL-OMON40506
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 9
Inclusion Criteria
Neuroblastoma patients treated with 131I-MIBG who developed differentiated thyroid carcinoma (and their parents <= control group)
Exclusion Criteria
Treatment with external irradiation
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To identify variants and structural variations that determine increased risk<br /><br>for secondary thyroid cancer. De novo germline aberrations as well as germline<br /><br>aberrations compared to the reference genome will be identified. In addition we<br /><br>will determine the somatic variants found in the tumor sample. </p><br>
- Secondary Outcome Measures
Name Time Method <p>-</p><br>